Aurora Cannabis Inc.

Aurora Cannabis Reaffirms Q2 Growth Guidance on EU, UK Expansion

Edmonton – September 18, 2026 -- Aurora Cannabis Inc. (TSX: ACB) (NASDAQ: ACB) reaffirmed its fiscal 2027 second-quarter guidance for sequential growth in net revenue and adjusted EBITDA, citing new EU-GMP capacity and expanding market share in Germany, Poland and the United Kingdom.

Safari Flower Company adds EU-GMP capacity after July certification

The Canadian medical cannabis producer said its recently acquired Safari Flower Company, which received EU-GMP certification in July, is expected to generate incremental net revenue and adjusted EBITDA in the coming quarters. The certification adds to Aurora's position as one of the world's largest indoor EU-GMP certified producers.

Aurora Cannabis Rejects Curaleaf's ATM Complaint, Calls Hostile Bid Inadequate

Edmonton – September 17, 2026 -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has dismissed Curaleaf Holdings' regulatory application to halt its at-the-market (ATM) share program, calling the move a distraction from an undervalued hostile takeover bid.

Aurora says its ATM program predates Curaleaf's bid by more than six months

The company confirmed its ATM program was publicly disclosed in February 2026, months before Curaleaf launched its hostile offer, and was designed to fund accretive acquisitions in Canada and the UK. Aurora said the program has been inactive for several weeks and had not been used for three years prior to February 2026.